Sign in or create an account to add this stock to your watchlist.
About Intec Pharma (NASDAQ:NTEC)
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NTEC
CUSIPN/A
Phone972-2586-4657
Debt
Debt-to-Equity RatioN/A
Current Ratio8.25
Quick Ratio8.25
Price-To-Earnings
Trailing P/E Ratio-2.79
Forward P/E Ratio-4.46
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.49 per share
Price / Book3.05
Profitability
EPS (Most Recent Fiscal Year)($1.65)
Net Income$-29,090,000.00
Net MarginsN/A
Return on Equity-70.95%
Return on Assets-65.20%
Miscellaneous
Employees70
Outstanding Shares32,830,000
Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions
What is Intec Pharma's stock symbol?
Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."
How were Intec Pharma's earnings last quarter?
Intec Pharma Ltd (NASDAQ:NTEC) announced its earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.13. View Intec Pharma's Earnings History.
When is Intec Pharma's next earnings date?
What price target have analysts set for NTEC?
6 brokers have issued 1-year target prices for Intec Pharma's shares. Their forecasts range from $10.00 to $16.00. On average, they anticipate Intec Pharma's stock price to reach $13.60 in the next twelve months. View Analyst Ratings for Intec Pharma.
Are investors shorting Intec Pharma?
Intec Pharma saw a decline in short interest in April. As of April 13th, there was short interest totalling 263,662 shares, a decline of 47.6% from the March 30th total of 503,544 shares. Based on an average daily trading volume, of 459,043 shares, the short-interest ratio is currently 0.6 days. Approximately 1.0% of the shares of the company are sold short.
Who are some of Intec Pharma's key competitors?
Some companies that are related to Intec Pharma include Clementia Pharmaceuticals (CMTA), StemlineTherapeutics (STML), AC Immune (ACIU), Aclaris Therapeutics (ACRS), Prothena (PRTA), Kura Oncology (KURA), Progenics Pharmaceuticals (PGNX), TiGenix (TIG), Achaogen (AKAO), Achillion Pharmaceuticals (ACHN), Evelo Biosciences (EVLO), Zealand Pharma (ZEAL), Insys Therapeutics (INSY), Isotechnika Pharma (AUPH) and ObsEva (OBSV).
Who are Intec Pharma's key executives?
Intec Pharma's management team includes the folowing people:
- Mr. Nir Sassi, Chief Financial Officer (Age 42)
- Dr. Nadav Navon Ph.D., Chief Operating Officer (Age 49)
- Mr. Zeev Weiss, Clinical and Bus. Devel. Consultant (Age 56)
- Mr. Jeffrey A. Meckler, Vice Chairman & CEO (Age 51)
- Mr. Walt Addison Linscott Esq., Chief Admin. Officer (Age 57)
When did Intec Pharma IPO?
(NTEC) raised $30 million in an initial public offering on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners acted as the underwriters for the IPO.
Has Intec Pharma been receiving favorable news coverage?
Headlines about NTEC stock have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Intec Pharma earned a daily sentiment score of 0.08 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 47.29 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Intec Pharma's major shareholders?
Intec Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Anson Funds Management LP (0.15%), Jane Street Group LLC (0.09%), ETF Managers Group LLC (0.09%) and JPMorgan Chase & Co. (0.07%). View Institutional Ownership Trends for Intec Pharma.
Which major investors are buying Intec Pharma stock?
NTEC stock was purchased by a variety of institutional investors in the last quarter, including Anson Funds Management LP, Jane Street Group LLC, ETF Managers Group LLC and JPMorgan Chase & Co.. View Insider Buying and Selling for Intec Pharma.
How do I buy shares of Intec Pharma?
Shares of NTEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intec Pharma's stock price today?
One share of NTEC stock can currently be purchased for approximately $4.55.
How big of a company is Intec Pharma?
Intec Pharma has a market capitalization of $151 million. The biotechnology company earns $-29,090,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Intec Pharma employs 70 workers across the globe.
How can I contact Intec Pharma?
Intec Pharma's mailing address is 12 Hartom Street Har Hotzvim, Jerusalem L3, 9777512. The biotechnology company can be reached via phone at 972-2586-4657 or via email at [email protected]
MarketBeat Community Rating for Intec Pharma (NTEC)
MarketBeat's community ratings are surveys of what our community members think about Intec Pharma and other stocks. Vote "Outperform" if you believe NTEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Intec Pharma (NASDAQ:NTEC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Intec Pharma in the last 12 months. Their average twelve-month price target is $13.60, suggesting that the stock has a possible upside of 198.90%. The high price target for NTEC is $16.00 and the low price target for NTEC is $10.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $13.60 | $13.60 | $12.00 | $12.00 |
| Price Target Upside: | 198.90% upside | 159.05% upside | 142.42% upside | 112.39% upside |
Intec Pharma (NASDAQ:NTEC) Consensus Price Target History
Intec Pharma (NASDAQ:NTEC) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Intec Pharma (NASDAQ:NTEC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Intec Pharma (NASDAQ NTEC) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 32.10%
Intec Pharma (NASDAQ NTEC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Intec Pharma (NASDAQ NTEC) News Headlines
| Source: |
|
Intec Pharma (NASDAQ:NTEC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Intec Pharma (NASDAQ:NTEC) Income Statement, Balance Sheet and Cash Flow Statement
Intec Pharma (NASDAQ NTEC) Stock Chart for Thursday, May, 24, 2018
Loading chart…
